Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Issue 1 (3rd November 2017)

• Record Type: Journal Article
• Authors: Bauer, Martin; Matsuda, Akihiro; Wulkersdorfer, Beatrix; Philippe, Cécile; Traxl, Alexander; Özvegy‐Laczka, Csilla; Stanek, Johann; Nics, Lukas; Klebermass, Eva‐Maria; Poschner, Stefan; Jäger, Walter; Patik, Izabel; Bakos, Éva; Szakács, Gergely; Wadsak, Wolfgang; Hacker, Marcus; Zeitlinger, Markus; Langer, Oliver
• Is Part Of: Clinical pharmacology & therapeutics. Volume 104:Issue 1(2018)
• Page Start: 139
• Page End: 147
• Publication Date: 2017-11-03
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.888
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : To assess the hepatic disposition of erlotinib, we performed positron emission tomography (PET) scans with [ 11 C]erlotinib in healthy volunteers without and with oral pretreatment with a therapeutic erlotinib dose (300 mg). Erlotinib pretreatment significantly decreased the liver exposure to [ 11 C]erlotinib with a concomitant increase in blood exposure, pointing to the involvement of a carrier‐mediated hepatic uptake mechanism. Using cell lines overexpressing human organic anion‐transporting polypeptides (OATPs) 1B1, 1B3, or 2B1, we show that [ 11 C]erlotinib is selectively transported by OATP2B1. Our data suggest that at PET microdoses hepatic uptake of [ 11 C]erlotinib is mediated by OATP2B1, whereas at therapeutic doses OATP2B1 transport is saturated and hepatic uptake occurs mainly by passive diffusion. We propose that [ 11 C]erlotinib may be used as a hepatic OATP2B1 probe substrate and erlotinib as an OATP2B1 inhibitor in clinical drug–drug interaction studies, allowing the contribution of OATP2B1 to the hepatic uptake of drugs to be revealed.